Cargando…
The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial
INTRODUCTION: Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical appl...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758240/ https://www.ncbi.nlm.nih.gov/pubmed/29390538 http://dx.doi.org/10.1097/MD.0000000000009381 |
_version_ | 1783290972536307712 |
---|---|
author | Li, Mo Lyu, Ji-hui Zhang, Yi Gao, Mao-long Li, Wen-jie Ma, Xin |
author_facet | Li, Mo Lyu, Ji-hui Zhang, Yi Gao, Mao-long Li, Wen-jie Ma, Xin |
author_sort | Li, Mo |
collection | PubMed |
description | INTRODUCTION: Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical application in China; the evidence-based efficacy of reminiscence therapy in AD patients remains to be determined. Therefore, the aim of this research is to assess the effectives of reminiscence therapy for Chinese elderly. METHODS AND ANALYSIS: This is a randomized parallel-design controlled trial. Mild and moderate AD patients who are in the Beijing Geriatric Hospital, China will be randomized into control and intervention groups (n = 45 for each group). For the intervention group, along with conventional drug therapy, participants will be exposed to a reminiscence therapy of 35 to 45 minutes, 2 times/wk for 12 consecutive weeks. Patients in the control group will undergo conventional drug therapy only. The primary outcome measure will be the differences in Alzheimer disease Assessment Scale-Cognitive Section Score. The secondary outcome measures will be the differences in the Cornell scale for depression in dementia, Neuropsychiatric Inventory score, and Barthel Index scores at baseline, at 4 and 12 weeks of treatment, and 12 weeks after treatment. ETHICS AND DISSEMINATION: The protocols have been approved by the ethics committee of Beijing Geriatric Hospital of China (approval no. 2015-010). Findings will be disseminated through presentation at scientific conferences and in academic journals. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier ChiCTR-INR-16009505. |
format | Online Article Text |
id | pubmed-5758240 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-57582402018-01-29 The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial Li, Mo Lyu, Ji-hui Zhang, Yi Gao, Mao-long Li, Wen-jie Ma, Xin Medicine (Baltimore) 4600 INTRODUCTION: Alzheimer disease (AD) is one of the most common diseases among the older adults. Currently, various nonpharmacological interventions are used for the treatment of AD. Such as reminiscence therapy is being widely used in Western countries. However, it is often used as an empirical application in China; the evidence-based efficacy of reminiscence therapy in AD patients remains to be determined. Therefore, the aim of this research is to assess the effectives of reminiscence therapy for Chinese elderly. METHODS AND ANALYSIS: This is a randomized parallel-design controlled trial. Mild and moderate AD patients who are in the Beijing Geriatric Hospital, China will be randomized into control and intervention groups (n = 45 for each group). For the intervention group, along with conventional drug therapy, participants will be exposed to a reminiscence therapy of 35 to 45 minutes, 2 times/wk for 12 consecutive weeks. Patients in the control group will undergo conventional drug therapy only. The primary outcome measure will be the differences in Alzheimer disease Assessment Scale-Cognitive Section Score. The secondary outcome measures will be the differences in the Cornell scale for depression in dementia, Neuropsychiatric Inventory score, and Barthel Index scores at baseline, at 4 and 12 weeks of treatment, and 12 weeks after treatment. ETHICS AND DISSEMINATION: The protocols have been approved by the ethics committee of Beijing Geriatric Hospital of China (approval no. 2015-010). Findings will be disseminated through presentation at scientific conferences and in academic journals. TRIAL REGISTRATION: Chinese Clinical Trial Registry identifier ChiCTR-INR-16009505. Wolters Kluwer Health 2017-12-22 /pmc/articles/PMC5758240/ /pubmed/29390538 http://dx.doi.org/10.1097/MD.0000000000009381 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 4600 Li, Mo Lyu, Ji-hui Zhang, Yi Gao, Mao-long Li, Wen-jie Ma, Xin The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial |
title | The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial |
title_full | The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial |
title_fullStr | The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial |
title_full_unstemmed | The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial |
title_short | The clinical efficacy of reminiscence therapy in patients with mild-to-moderate Alzheimer disease: Study protocol for a randomized parallel-design controlled trial |
title_sort | clinical efficacy of reminiscence therapy in patients with mild-to-moderate alzheimer disease: study protocol for a randomized parallel-design controlled trial |
topic | 4600 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5758240/ https://www.ncbi.nlm.nih.gov/pubmed/29390538 http://dx.doi.org/10.1097/MD.0000000000009381 |
work_keys_str_mv | AT limo theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT lyujihui theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT zhangyi theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT gaomaolong theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT liwenjie theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT maxin theclinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT limo clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT lyujihui clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT zhangyi clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT gaomaolong clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT liwenjie clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial AT maxin clinicalefficacyofreminiscencetherapyinpatientswithmildtomoderatealzheimerdiseasestudyprotocolforarandomizedparalleldesigncontrolledtrial |